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ABSTRACT 
Background: Symptom relief in peripheral arterial disease (PAD) can be obtained by 
invasive options such as endovascular stenting as well as exercise, and PAD medications. 
Each of these options have their own risks and benefits. A lack of knowledge about treatment 
options, risks and benefits, and how these matter to the patient, as well as a lack of support 
relating to treatment decisions can result in decisional conflict. We aimed to (1) document 
decisional conflict in patients facing PAD treatment decisions; (2) examine site variability in 
decisional conflict; and (3) examine whether decisional conflict is associated with PAD 
treatment strategy and 1-year health status outcomes. 
Methods: The PORTRAIT study is an observational prospective study that enrolled patients 
with new or an exacerbation of PAD symptoms from 16 PAD specialty clinics in the US, the 
Netherlands, and Australia. Patients were interviewed before they underwent PAD treatments 
to document their socio-economic background and their health status (Peripheral Artery 
Questionnaire – PAQ). Medical history was abstracted from the medical records. At 3 
months, treatment information and decisional conflict (yes/no – 4-item SURE instrument) 
information was collected from the patient. One-year follow-up health status information was 
collected by phone interview. Median odds ratios were calculated to quantify the level of site 
 iv
variability. A multivariable logistic regression model was constructed to examine the 
association between decisional conflict and primary PAD treatment strategy (invasive vs. 
non-invasive). A multivariable linear regression model was built to examine the association 
between decisional conflict and 1-year PAQ summary scores, while adjusting for baseline 
PAQ summary scores.  
Results: The unadjusted median odds ratio (MOR) for site variability was 2.01 (95% CI 
1.56-3.13; p<0.001), after adjusting for country, the MOR was 1.12 (95% CI 1.00-1.46; 
p=0.35). After adjustment for site and relevant patient covariates, decisional conflict was 
associated with lower odds of receiving invasive treatment (OR=0.58; 95% CI 0.34-1.00; 
p=0.050). Decisional conflict was also associated with lower 1-year health status gains for 
the PAQ summary score (adjusted B=-4.72; 95% CI -9.38;-0.06; p=0.047), even adjusting for 
primary PAD treatment strategy. 
Conclusion: One in five patients facing PAD treatment decisions experience decisional 
conflict. While there is considerable variation for the occurrence of decisional conflict, it is 
more common among non-US countries. As compared with patients who do not experience 
decisional conflict, those reporting conflict are more often managed non-invasively and 
experience lesser 1-year health status gains, not entirely explained by the primary PAD 
treatment modality. Increasing knowledge and support for non-invasive PAD treatment 
options may be ways to reduce decisional conflict in PAD.  
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CHAPTER 1 
INTRODUCTION 
 Peripheral artery disease (PAD) affects 8.5 million Americans—approximately one 
in 16 Americans over 40 years old.1 Its prevalence increases with age, with rates as high as 
20% among those over 80-years old.2 Recent global estimates suggest that PAD has been on 
the rise in low- to middle-income as well as high-income countries.3  
The pathophysiology of PAD is most often explained by atherosclerosis of the lower 
extremity arteries, restricting the blood flow in the leg arteries. If symptomatic, PAD causes 
pain in the lower extremities clinically referred to as claudication. Common risk factors 
include smoking, diabetes, older age, obesity, hypertension, hypercholesterolemia, and a 
family history of PAD.4 Patients with PAD are known to be high risk for fatal and non-fatal 
cardiovascular events (such as myocardial infarction or stroke) with rates that are 
disproportionately high as compared with coronary and cerebrovascular disease.5 Despite its 
high burden, it is well documented that PAD is under-recognized and undertreated.6  
 PAD is generally diagnosed when a patient first presents with mild claudication 
symptoms. The primary goals of PAD treatment are cardiovascular risk reduction and 
symptom relief. Patients should routinely be offered antiplatelet and statin therapy, and 
patients who smoke should be referred for smoking cessation counseling. As for the 
symptom management, PAD can be treated invasively through endovascular and surgical 
revascularization procedures but symptoms can also be managed through claudication 
medications and supervised or home-based exercise therapy.7 Due to the availability of a 
myriad of treatment options with no clear gold standard identified and acceptable risks and 
benefits for more than one alternative strategy to obtain symptom relief in PAD, clinical 
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equipoise is present.8 Care in these scenarios is sensitive to patients’ needs, preferences and 
values.9 Ideally, the choice of treatment and associated risks and benefits should align with a 
patient’s individual preferences. When patients’ preferences are not taken into account, and 
instead, provider or system factors may guide the treatment decision, there is a potential for 
unwanted variation and outcomes.10 Shared decision-making (SDM) offers a useful 
framework to reduce undesired provider- or system-related variations in treatment allocation 
and can stimulate a more engaged and preference-sensitive decision-making process.11 
 SDM refers to an interaction between a patient and provider to achieve mutual 
treatment goals. The inclusion of SDM in the clinical setting allows patients to review 
evidence for available treatment options and empowers patients to make treatment decisions 
weighing the potential risks and benefits against their preferences.12 One of the central goals 
of SDM is to allow patients to become more engaged in their interactions with the provider, 
both for those who typically take more passive roles and those who wish to take a more 
active role in their health care.13 
 The SDM process consists of simple actions patients and their care team can do when 
making shared clinical decisions.14 This process can be seen in flow chart form in Figure 1. 
Moving from the spectrum of an uninformed patient to an informed one, the patient first must 
convene with their care team to promote the patient’s support network and discuss the 
importance of examining options. Next, describing the relevant options is a critical piece to 
making the best decision. In the case of PAD, this would mean being presented with all 
possible treatments in the invasive to non-invasive spectrum and its associated risks and 
benefits. If a tool were implemented to help a patient weigh the risks and benefits of a 
treatment plan (a decision aid), this second step would be an ideal time to do so. Third, a 
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patient should discuss their personal values as they relate to their health and desired 
outcomes. The patient should understand the amount of risks and benefits are involved for 
each treatment and discuss how those ratios align with their health preferences. As a last step, 
the patient will complete the SDM process if they decide on a relevant treatment that matches 
their preference. If the SDM process is unsuccessful, the patient may experience a degree of 
decisional conflict about the treatment choice. Decisional conflict can result when a patient 
lacks knowledge about their choice, they are unaware of the choices available to them, they 
do not understand the benefits and risks associated with each choice, or they do not have the 
necessary support to make a decision.15 
 A Cochrane Review on decision-making aids found that implementation of clinical 
decision aids had immediate effects of increasing patient knowledge of treatment options, 
resulted in more accurate patient perception of treatment risks, and empowered patients to 
choose treatment options that are more aligned with their values.12 The review also showed 
that decision aids reduced decision conflict, moved patients away from a passive role to more 
active roles in their decision-making, and decreased the inability to actually make decisions.  
 In addition to these near-term effects of better informed patients who make preference-
based treatment decisions, mid-term effects (Figure 2) are that patients tend to choose safer, 
more cost-effective options that align with their personal values.14 By choosing treatments 
that better align with patient values, long-term effects of more efficient usage of resources 
and overall improved outcomes are expected. In theory, the near-term, mid-term, long-term 
effect cycle will positively feed back into everyday clinical decision-making in the clinic 
preventing decisional conflict and promoting better outcomes, more treatment satisfaction, 
and better quality of life.16 Besides positive health effects, SDM has significant economic 
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implications. When given the choice, patients tend to choose less invasive options, which are 
typically less expensive.17 
 It is unclear what the quality of the decision-making process is for patients with a new 
or an exacerbation of PAD. The Patient-centered Outcomes Related to Treatment practices in 
peripheral Arterial disease: Investigating Trajectories (PORTRAIT) study was specifically 
designed to collect prospective information about the quality of the medical decision process, 
the care that patients were assigned to, and subsequent outcomes in patients managed for 
their PAD in a specialty care setting. In prior work, we documented that up to 19% of PAD 
patients in the PORTRAIT study report a discordant experience between their desire to be 
involved in the decision-making process and the way the actual decision took place18 and 
21% of patients expressed having had experienced decision conflict over their decision-
making for PAD treatment.19 It is unknown, however, how these initial decision experiences 
vary across PAD specialty clinics and how they are linked to actual treatment choice and 
subsequent health status outcomes. 
 To address these gaps in knowledge, we aimed to 1) document the site variability for 
the occurrence of decisional conflict in patients seen at PAD specialty clinics; 2) examine the 
association between the occurrence of decision conflict in PAD treatment and the primary 
PAD treatment patients underwent following their evaluation at the clinic (invasive versus 
non-invasive) and, 3) document the association between decision conflict and 1-year changes 
in PAD specific health status outcomes. Specifically, we hypothesize that decision conflict 
varies considerably across sites and that it exists in patients undergoing invasive treatment 
options. We also hypothesize that decision conflict is associated with less health status gains 
as compared with those who do not experience decision conflict. This knowledge will inform 
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future studies in SDM for PAD treatment and will help design interventions to implement 
protocols of SDM that may have the potential to increase patient engagement and reduce 
decision conflict for PAD treatment decisions.  
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CHAPTER 2 
METHODS 
Study Design and Patients 
The PORTRAIT study is a multi-centered, prospective, observational registry 
organized at 16 PAD specialty clinics in the United States of America (Figure 5), The 
Netherlands (Figure 6), and Australia (Figure 7). Inclusion and exclusion criteria are shown 
in Table 1.20 
 Patients were recruited if they presented with an abnormal ankle-brachial index (ABI) 
and new-onset or worsening claudication symptoms. Prior to receiving PAD treatment, 
patients were interviewed by trained data collectors to obtain information about 
sociodemographic factors, psychosocial characteristics, their health status, and shared 
decision-making preferences. Demographic, clinical, and treatment information was 
abstracted from patients’ medical records. Follow-up health status data was collected through 
centralized telephone interviews at 3, 6 and 12 months after enrollment. Treatment and 
information about decision making was obtained at the 3 month follow-up. Therefore, any 
treatments recorded would have occurred between the baseline interview and the 3 month 
time point. Figure 3 describes the data collection process. 
The PORTRAIT study was approved by the coordinating center St. Luke’s Health 
System’s internal review board in Kansas City, Missouri, USA, and by the local ethical 
committees at each enrolling site. Informed consent was obtained from all participants.  
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Measures 
Decision conflict refers to the feeling that one has insufficient knowledge or comfort 
about a medical decision21 and was screened for by the SURE Instrument (Table 2). This 4-
item screener was developed in a Canadian and rural US population based on the Decisional 
Conflict Scale22 and has shown to be a reliable screening tool in both French- and English-
speaking populations.15 The SURE tool has been validated against the Decisional Conflict 
Scale with at 94.1% (95% CI 78.9-99.0) sensitivity and 89.8% (95% CI 87.1-92.0) specificity 
for identifying decisional conflict.23 The SURE instrument uses four yes or no questions to 
determine if decision conflict has occurred in a patient’s medical decision-making process. A 
“Yes” answer is scored as 1 and a “No” answer as 0; a composite score of less than 4 is an 
indicator for decision conflict. 
PAD Treatment Information was obtained from the 3-month patient interviews. All 
peripheral revascularization procedures were captured including lower-extremity 
percutaneous transluminal angioplasty (with or without stenting), bypass surgery, 
endarterectomy, and atherectomy. Information about referral and attendance of a supervised 
or home-based exercise program was also collected from this interview. This included 
collecting information about whether the patient took part in PAD-specific, unsupervised 
exercise therapy, PAD-specific, supervised exercise therapy, or non-PAD specific exercise 
therapy. Patients were asked about the frequency and duration of their participation, whether 
they were still participating, and the reasons for stopping if applicable. This information was 
used to describe patient adherence to exercise therapy. 
PAD-Specific Health Status was measured by the Peripheral Artery Questionnaire 
(PAQ), a validated, 20-item health status instrument with the following dimensions: physical 
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limitation, symptoms (frequency, severity, change over time), quality of life, social function 
and treatment satisfaction.24 A summary score can be calculated based on the physical 
limitation, symptom frequency/burden, social function, and quality of life domains. Each of 
these scales is scored along different Likert scales. Scores on each domain and the summary 
scale can be calculated using a standardized algorithm and range from 0-100 with higher 
scores representing better health status. The PAQ has good internal validity and test-retest 
reliability.24 
Other Covariate Information included variables relevant to the patients and their 
PAD treatment. These variables included demographic information, such as age, sex, and 
race. It included socioeconomic factors such as education level and insurance status. Medical 
history and vital information were collected through medical chart abstractions. Information 
on the patient’s PAD characteristics was collected including typical or atypical symptoms 
using the San Diego Claudication Questionnaire25, ankle brachial index, Rutherford index26, 
and the highest claudication location. Smoking status was assessed using questions based on 
BRFSS and Question Inventory on Tobacco27, alcohol consumption using AUDIT-C28, as 
well as psychosocial health using the ENRICHD social support inventory29. The patient’s 
provider type and preferences for shared decision making were collected using the Deber 
Questionnaire30. Information about medications, dosage, and frequency were collected in 
addition to reasons for not taking medication using the 2010 Performance Measures31 and 
medication adherence using Medication Discussion Questions32. 
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Statistical Analysis 
 Based on the SURE instrument results, all participants were categorized into either 
the “Decision Conflict Present” or the “Decision Conflict Not Present” group. Patient 
characteristics, primary PAD treatment strategy, and baseline and 1-year health status scores 
were described and compared by the presence of decisional conflict. Student’s t-test were 
used for continuous variables and Chi-square or Fisher’s exact text for categorical variables, 
where appropriate. Normality was confirmed in continuous scores, and if needed, non-
parametric options (Mann–Whitney U test) were used.  
 We examined site variability by calculating median odds ratios and constructing 95% 
confidence intervals around the median odds ratio. The median odds ratio is used to make 
comparisons for randomly selected participants from different groupings. In this case, 
between the different clinic sites. Median odds ratios are used in place of interpreting a 
random or fixed effect for site in a participant specific analysis. If the median odds ratio is 
one, there is no variation at the site level. A ratio greater than one represents significant 
between-site variation.33 
 A multivariable logistic regression model was created to examine the relationship 
between decision conflict and primary treatment choice. Covariates were sequentially entered 
in step-wise blocks to better understand which type of variables impacted the association 
between decisional conflict and treatment choice. The step-wise blocks were as follows: (1) 
decision conflict present or absent; (2) country, site, and provider specialty; (3) age, sex, and 
race (white versus not white); (4) marital status (not married versus married), education level 
(less than high school education versus high school education or greater), and insurance 
status (no insurance versus any form of insurance) (5) ankle brachial index, disease location 
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(proximal, distal, or both) and history of peripheral arterial disease (as classified by a 
previous peripheral vascular atherectomy, endarterectomy, bypass surgery, or angioplasty); 
(6): history of acute myocardial infarction, history of stroke, history of heart failure, smoking 
status, and diabetes; and (7): whether or not the patients’ preferred role in decision making 
was passive or not passive.  
For the logistic regression model, assumptions were tested prior to the analysis. 
Linearity of continuous covariates was assessed by analyzing the natural logarithmic 
transformation of these variables. No variables showed significant values, thus there were no 
linear relationships present. Data cases were all independent. Multicollinearity was assessed 
by analyzing correlation coefficients between variables. No correlations greater than 0.70 
existed between variables. There were no outliers. Inclusion in the outcome variable was 
mutually exclusive and collectively exhaustive. Hosmer-Lemeshow analysis was not 
significant (p = 0.715). 
 A multivariable linear regression model was created to examine the association 
between decisional conflict and 1-year PAQ summary scores. Sequential adjustments were 
made for the following covariates, in step-wise blocks: (1) decision conflict present or 
absent; (2) country, site, provider specialty, and PAQ summary baseline scores; (3) age, sex, 
and race (as white versus not white); (4) marital status, education level, and insurance status; 
(5) ankle brachial index, disease location (proximal, distal, or both), and history of peripheral 
arterial disease; (6) history of acute myocardial infarction, history of stroke, history of heart 
failure, smoking status, and diabetes; (7): treatment as four levels (non-invasive, no exercise 
therapy; non-invasive, exercise therapy; invasive, non-exercise therapy; and invasive, 
exercise therapy); and (8): passive vs. a non-passive role preference for decision-making.  
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 For the multivariable linear regression model, assumptions were tested prior to the 
analysis. No multicollinearity existed in the data. No correlations greater than 0.70 existed 
between variables. There was homoscedasticity of residuals. There was a generally normal 
distribution of errors as assessed by normality and P-P plots. Durbin-Watson (2.032) showed 
outcome independence. There was a linear relationship between covariates and outcomes. 
 Analyses were conducted with SPSS Software version 24 (IBM corporation, Armonk, 
New York, USA) and with SAS version 9.4 (SAS Institute, Cary, North Carolina, USA). All 
tests performed were two-tailed and p-values less than 0.05 were considered statistically 
significant. Complete case analyses were performed. 
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CHAPTER 3 
RESULTS 
A total of 3,637 patients were screened for the PORTRAIT study. Of these, 1,608 
(44.3%) were found to be eligible and 1,275 (79.3%) consented to participate. For our 
analytic cohort, 166 patients were excluded due to missing scores on our primary variable of 
interest (decisional conflict), leaving 1,109 patients within the analyses after exclusion. 
A total of 231 (20.8%) patients reported experiencing decisional conflict. The 
frequencies for each item of the SURE-instrument patients (Table 3) was in accordance with 
the number of items patients expressed decisional conflict over (Table 4). The item that 
patients felt most conflicted about was the ‘risks and benefits of treatment’ item, followed by 
the ‘risks and benefits that matter most’ item.  
 Table 6 shows an overview of patient characteristics by the experience of decisional 
conflict or no decisional conflict. Compared with those who did not experience decisional 
conflict, patients that felt conflicted about their treatment decision were more likely to be 
white, less likely to have obtained a high school education, but more often had insurance. 
They had a different localization of their symptoms were less likely to have had a history of 
peripheral vascular intervention. Patients with decisional conflict less often presented with 
risk factors such as dyslipidemia and hypertension, or a history of percutaneous coronary 
intervention or coronary artery bypass grafting, but presented more often with chronic back 
pain. Patients with decisional conflict also reported lower treatment satisfaction and social 
support scores. Patients who reported decisional conflict, were most often enrolled from the 
vascular surgery setting, and from the Netherlands and Australia. They also reported 
adopting a more passive role for their decision making, and experiencing more discordance 
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between their preferred role for their decision-making and how the actual decision-making 
occurred. More patients with decisional conflict were referred for exercise therapy, 
particularly unsupervised therapy. 
Site variability was examined using median odds ratios and 95% confidence intervals 
(CI) shown in Table 5 and Figure 8. The overall, unadjusted median odds ratio (MOR) was 
2.01 (95% CI 1.56-3.53, p < 0.001). This value was no longer statistically significant after 
adjusting for country 1.12 MOR (95% CI 1.00-1.46, p = 0.35).  
 The results of the logistic regression modeling are provided in Error! Reference 
source not found.. In step 1, the estimate for the association between decisional conflict and 
non-invasive treatment referral was OR= -0.49; 95% CI 0.36-1.03; p = 0.07. Throughout the 
sequential adjustment of covariates, the estimate remained robust. In the fully adjusted model 
(after adding block 7), decisional conflict remained significantly associated with a referral to 
a non-invasive treatment strategy (Odds Ratio [OR] = -0.54; 95% CI 0.34-1.00; p = 0.050. 
Full model results are depicted in Table 10. 
 An overview of the multivariable linear regression results is shown in Error! 
Reference source not found.. In the step 1, decisional conflict was significantly associated 
with smaller 1-year health status improvements as compared with those who did not 
experience decisional conflict: B= -4.77; 95% CI -9.51-(-0.03); p-value 0.049. In the fully 
adjusted model, the association persisted after block 7 was introduced (B = -4.72; 95% CI -
9.38-(-0.06); p = 0.047).  
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CHAPTER 4 
DISCUSSION 
 One in five patients in the PORTRAIT study reported experiencing decisional 
conflict with regards to their PAD treatment. Significant variability across PAD specialty 
clinics was observed for the occurrence of decisional conflict, mostly explained by country 
variations in decisional conflict. Patients that expressed decisional conflict vs. those who did 
not were more likely to be white, insured, and less affected by cardiovascular risk factors, but 
more burdened by chronic back pain. They were more often referred to non-invasive PAD 
treatment strategies as opposed to invasive revascularization treatments.  
Having decisional conflict was also associated with less improvement in 1-year PAD-
specific health status scores as compared with those who did not experience decisional 
conflict. While the association attenuated when adjusting for the primary treatment modality 
in the health status, initial explorations indicated that decisional conflict more often occurred 
among those receiving unstructured instructions for exercise therapy and that no clear 
indications for non-adherence issues were found among those expressing decisional conflict.  
This is the first study that examines aspects of the decisional quality of PAD 
treatment decisions in a specialty care setting. There are several treatment options available 
to manage PAD symptoms, with each of these options having different trade-offs in terms of 
risk, durability and timeline of benefits. In fact, recent clinical trial evidence from the 
CLEVER study demonstrated that both endovascular stenting options and supervised 
exercise therapy offer durable symptom relief of the same magnitude in patients with aorto-
illiac disease.34  
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It is therefore important that patients’ treatment is matched to their preferences and 
that patients are set up for success to make the treatment choice that aligns with their goals 
and preferences. Patients would need to have adequate knowledge and support to have 
informed and engaged discussions about their treatment with their providers. Virtually no 
information about these aspects of the decision-making process has been described as it 
relates to PAD. As a substantial subgroup experiences conflict surrounding their PAD 
treatment choice. The experience of conflict seems to be associated with less successful 
outcomes in terms of patients’ health status. This study has the potential to highlight aspects 
of the decision-making process that may be amenable to change and could lead to insights 
that may help improve the decision-making process and potentially also subsequent 
outcomes for PAD.  
We observed significant variation across sites as to whether patients were 
experiencing decisional conflict. Most of this variability was explained by country 
differences. As was demonstrated in prior preliminary work, significant country differences 
exist in the occurrence of decisional conflict and in preferred roles with regards to patients’ 
decision-making.35 Patients from non-US countries tend to have a preference for adopting a 
more passive role in their decision-making process, and from literature, it is known that a less 
engaged role in this process is associated with the experience of more decisional conflict.12 
Importantly, shared decision-making interventions have been designed and tested in patients 
with cardiovascular disease to demonstrate that patients can be encouraged to move from 
passive roles to more engaged interaction styles with regards to their medical decision-
making process.36  
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Given prior literature that demonstrated that patients who are more informed and 
engaged tend to choose less invasive options for their treatment,37 we expected that 
decisional conflict would be associated with invasive treatment options. In contrast, we 
observed a conflict for patients who received a non-invasive management strategy for their 
PAD symptoms. When characterizing patients by decisional conflict, there were indications 
that decisional conflict seems to be present particularly among those with unsupervised forms 
of exercise therapy, and those who said they were not offered a supervised form of exercise 
therapy. Decisional conflict remained a key factor in PAD treatment even after adjusting for 
multiple levels of factors. It is likely that patients who underwent invasive procedures did not 
experience as much conflict since providers are mandated to educate their patients on the 
procedure(s), risks, benefits, and probable outcomes for each treatment. There is certainly an 
acceptable amount of infrastructure and support surrounding the more invasive, higher-risk 
procedures as opposed to conservative PAD management strategies. 
When linking the experience of decisional conflict to 1-year health status changes, we 
could demonstrate that patients who experience decisional conflict, had less PAD-specific 
health status gains, as compared with those who did not experience decisional conflict. It is 
unclear whether this association can solely be explained by the expected gains of the 
treatment modalities to which patients were assigned. The CLEVER results would argue 
against this notion, and was able to demonstrate that the non-invasive treatment of PAD 
symptoms through supervised exercise therapy can be equally beneficial as compared with 
stenting.8 Adjusting for treatment modality did not attenuate the association between 
decisional conflict and worse 1-year health status gains in our analyses. Another potential 
explanation that we considered was whether patients who experienced decisional conflict 
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were less adherent in terms of their exercise and medication recommendations. From our 
initial descriptive comparisons, we found no clear indications that patients who experienced 
decisional conflict were different in terms of their adherence behaviors. The degree to which 
sufficient time, detail, support was spent when giving instructions for the non-invasive 
management of patients’ PAD symptoms and what referrals were made, could really be the 
key information that may further help understand the less optimal benefits obtained in 
patients’ 1-year health status. Therefore, it may well be that decisional conflict may not be a 
driver for suboptimal quality of life outcomes but rather that it may be a marker for a lack of 
adequate information, support, and preparedness for patients who are being managed with 
non-invasive options. Further work should further explore this notion.  
Efforts to reduce decisional conflict have mainly focused on decision aids designed to 
increase knowledge of clinical options, weigh risks and benefits, describe implications for 
outcomes, increase patient satisfaction, and outline financial burdens that may result.38-42 
Most of these interventions are designed within the context of the shared-decision making 
paradigm. The design of educational tools or decision aids that summarize the evidence as it 
relates to risks and benefits of PAD treatment strategies to relieve patients’ symptoms will be 
an important next step when designing interventions that can increase knowledge, stimulate 
the engagement with their providers as it relates to the decision-making process for managing 
PAD symptoms. Important future work would develop and implement better structural 
solutions to offer non-invasive management strategies for PAD symptoms. Access to, 
reimbursement, and availability of supervised exercise programs is key to set patients up for 
success. In addition, as PAD is a chronic disease that needs to be managed through targeting 
complex risk factors, one can also imagine that multidisciplinary, behavioral disease 
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management programs would need to be designed and tested to facilitate the non-invasive 
management of this disease and to optimize patients’ health status outcomes.  
Our results should be interpreted against the following limitations: First, information 
on the primary treatment strategy was patient-reported, and potential misclassification may 
have occurred. As abstraction and adjudication efforts are underway, we will be able to 
reconcile our results using the medical record treatment information. Second, our study was 
observational and there are possible risks of residual confounding and biases related to the 
treatment selection process. Our results need to be validated in other cohorts, treatment 
effects need to be further explored by reducing the potential for bias (e.g. with propensity 
score methodology), and future randomized studies with a focus on reducing decisional 
conflict may help address these potential biases. Third, we did not complete a formal 
mediation or moderator analysis and our explorations into potential explanations of the 
observed associations should mainly be viewed as hypothesis generating. Fourth, decisional 
conflict scores may have been impacted by the timing of patients’ pending intervention, and 
future work may need to incorporate the timing of the intervention or the treatment 
discussion when interpreting the decisional conflict scores. Finally, 1-year health status 
outcomes may also have been impacted by whether or not technical success occurred and 
whether or not patients received intermediate treatments between the 3-month and 1-year 
time- mark.  
Shared decision-making shows promise to achieve better quality of life for patients, 
specifically demonstrated in a population of peripheral arterial disease patients in this study. 
By identifying areas where shared decision-making does not occur and the reasons why it 
does not occur, further work can be done to provide strategies for empowering patients to 
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make informed clinical decisions, which would hopefully result in better overall outcomes. 
By exchanging evidence for these metrics, it is possible for the creation of predictive models 
for use by teams of providers and patients and supports a value-based care model rather than 
one on performance.  
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TABLES AND FIGURES  
Table 1. PORTRAIT Study Inclusion and Exclusion Criteria 
 
 
 
 
 
 
 
Inclusion Criteria Exclusion Criteria 
• Age ≥ 18 years 
• New-onset or recent exacerbation of 
exertional leg symptoms, regardless 
of whether symptoms are typical or 
atypical (buttock, thigh, hip or calf 
pain, numbness or discomfort 
inhibiting the patient’s ability to 
walk distances)  
• Ankle-brachial index = resting 
ankle-brachial index assessment 
≤0.90 or drop in post-exercise ankle 
pressure ≥20mmHg 
• Non-compressible ankle-brachial 
index (ABI ≥1.30) 
• Patient had a lower-limb 
revascularization procedure in the 
ipsilateral leg where the patient is 
currently having symptoms in the 
past year (atherectomy, 
endarterectomy, bypass surgery, 
angioplasty) 
• Patient presents with a current 
episode of critical limb ischemia 
(ischemic rest pain, ulceration or 
gangrene) (Fontaine III, IV, or 
Rutherford grade IV-VI) 
• Non-English speaking or non-
Spanish speaking for US sites; Non-
Dutch speaking for Dutch sites; 
Non-English speaking for Australian 
sites 
• Hearing impairment 
• Currently a prisoner 
• Patient previously enrolled in 
PORTRAIT study 
• Unable to provide written informed 
consent 
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Table 2. SURE Instrument Categories and Questions; Used to Determine the Presence or 
Absence of Decisional Conflict—A No Answer in Any Category Results in Decisional 
Conflict Presence 
Acronym Category Test Question 
Sure of Myself 
Do you feel sure about the best choice for 
you?  
Understand Information 
Do you know the benefits and risks of each 
option? 
Risk-benefit Ratio 
Are you clear about which benefits and 
risks matter most to you? 
Encouragement 
Do you have enough support and advice to 
make a choice? 
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Table 3. Number of Patients (%) in Agreement with Individual SURE Items.  
SURE Question Agreed (%) 
Do you feel sure about the best choice for 
you? (3 months) 
995 (89.7) 
Do you know the benefits and risks of each 
option? (3 months) 
963 (86.8) 
Are you clear about which benefits and 
risks matter most to you? (3 months) 
964 (86.9) 
Do you have enough support and advice to 
make a choice? (3 months) 
990 (89.3) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 23
Table 4. Overview of the number of patients (%) by the number of items they expressed 
decisional conflict over in the SURE instrument at 3 Months.  
Number of Items on the SURE Instrument 
Expressing Decisional Conflict 
Patients (%) 
0   878 (79.2) 
1  87 (7.8) 
2  55 (5.0) 
3  29 (2.6) 
4  60 (5.4) 
SURE Test Decisional Conflict Present 231 (20.8) 
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Table 5. Median Odds Ratios Used to Assess Site Variability. Includes Number of Sites, 
Median Odds Ratios with 95% Confidence Intervals, and P-Values. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Number of Sites Median Odds Ratio 
(95% CI) 
P-Value 
Overall 15   
Unadjusted  2.01 (1.56, 3.13) < 0.001 
Adjusted for 
Country 
 1.12 (1.00, 1.46) 0.35 
By Country    
United States 9 1.32 (1.00, 1.98) 0.06 
The Netherlands 5 1.00 (1.00, 1.41) 0.99 
Australia 1 N/A N/A 
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Table 6. Socio-Demographic, Medical History, and Health Status Factors in Patients 
Stratified by Decision Conflict Present or Not-Present. Counts, Local Percentages, and P-
Values. 
 Decisional Conflict 
(N=231) 
No Decisional 
Conflict (N=878) 
P-Value 
Demographics 
Age 67.5±9.1 67.5±9.4 0.96 
Sex   0.23 
Male 153 (66.2) 544 (62.0)  
Female 78 (33.8) 334 (38.0)  
Race: White/Caucasian 207 (89.6) 710 (80.9) 0.001 
Married 131 (57.5) 520 (59.5) 0.58 
Currently working for pay 
at baseline 
  0.22 
No 183 (79.6) 655 (74.9)  
Yes, full-time 32 (13.9) 132 (15.1)  
Yes, part-time 15 (6.5) 87 (10.0)  
Socio-Economic Factors 
≥ High school education 117 (52.0) 634 (72.5) <0.001 
Insurance 210 (90.9) 653 (74.4) <0.001 
Avoid care due to cost at 
baseline 
31 (13.5) 120 (13.8) 0.91 
Finances at the end of the 
month at baseline 
  0.67 
Some money left over 120 (54.5) 479 (55.8)  
Just enough to make 
ends meet 
74 (33.6) 296 (34.5)  
Not enough to make 
ends meet 
26 (11.8) 84 (9.8)  
Disease Characteristics 
Function in Symptomatic 
Leg 
  0.19 
Right leg 50 (21.6) 223 (25.4)  
Left leg 66 (28.6) 204 (23.2)  
Both legs 115 (49.8) 451 (51.4)  
Function: Claudication 231 (100) 874 (99.5) 0.59 
Function: Location of 
highest claudication 
  0.026 
Buttock 48 (20.8) 142 (16.2)  
Hip 18 (7.8) 78 (8.9)  
Thigh 29 (12.6) 141 (16.1)  
Calf 109 (47.2) 454 (51.9)  
Foot 9 (3.9) 12 (1.4)  
Other 18 (7.8) 47 (5.4)  
   0.28 
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 Decisional Conflict 
(N=231) 
No Decisional 
Conflict (N=878) 
P-Value 
Function: Rutherford 
category 
Mild claudication 59 (26) 183 (21.1)  
Moderate claudication 108 (47.6) 436 (50.2)  
Severe claudication 60 (26.4) 250 (28.8)  
Ankle brachial index 0.67±0.19 0.70±0.19 0.53 
Lesion Site   0.95 
Proximal 136 (58.8) 399 (45.4)  
Distal 16 (6.9) 46 (5.2)  
Pain free walking distance 
(meters) 
136.0±184.7 120.7±105.2 0.35 
Duration of pain   0.91 
< 1 month 6 (3.2) 20 (2.6)  
1-6 months 57 (30.3) 223 (29.5)  
7-12 months 31 (16.5) 140 (18.5)  
> 12 months 94 (50.0) 373 (49.3)  
Symptom presentation   0.25 
Typical 177 (84.3) 709 (87.3)  
Atypical 33 (15.7) 103 (12.7)  
Medical History—Vascular 
Amputation 3 (1.3) 9 (1.0) 0.72 
Peripheral vascular 
intervention 
49 (21.2) 255 (29.0) 0.017 
Medical History—Other 
BMI 29.2±6.4 29.0±6.5 0.70 
Mean arterial pressure 105.4±74.7 95.5±26.2 0.004 
Atrial fibrillation 23 (10.0) 102 (11.6) 0.48 
Congestive heart failure 20 (8.7) 81 (9.2) 0.79 
Dyslipidemia 166 (71.9) 709 (80.8) 0.003 
Hypertension 172 (74.5) 711 (81.0) 0.028 
TIA/CVA 28 (12.1) 100 (11.4) 0.76 
Prior MI 35 (15.2) 169 (19.2) 0.15 
PCI/CABG 59 (25.5) 324 (36.9) 0.001 
Prior pacemaker 7 (3.0) 24 (2.7) 0.81 
Prior ICD 3 (1.3) 19 (2.2) 0.59 
Smoking status   0.60 
Never 25 (10.9) 91 (10.4)  
Former 114 (49.6) 467 (53.2)  
Current 91 (39.6) 319 (36.4)  
Erectile dysfunction 16 (6.9) 47 (5.4) 0.36 
Chronic kidney disease 20 (8.7) 99 (11.3) 0.25 
Chronic lung disease 39 (16.9) 151 (17.2) 0.91 
Sleep apnea 17 (7.4) 75 (8.5) 0.56 
Osteoarthritis (hip or knee) 18 (7.8) 82 (9.3) 0.46 
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 Decisional Conflict 
(N=231) 
No Decisional 
Conflict (N=878) 
P-Value 
Chronic back pain 43 (18.6) 111 (12.6) 0.019 
Alcohol consumption 90 (39.3) 295 (33.8) 0.12 
Cancer 26 (11.3) 86 (9.8) 0.51 
Depression requiring 
treatment 
27 (11.7) 108 (12.3) 0.80 
Diabetes 76 (32.9) 291 (33.1) 0.94 
PAQ Health Status at Baseline 
Physical limitation 41.1±27.6 38.3±25.9 0.17 
Symptom stability 41.3±22.1 44.3±21.0 0.07 
Symptoms 42.2±23.1 45.0±22.4 0.09 
Treatment satisfaction 78.7±22.0 84.7±20.3 <0.001 
Quality of Life 50.6±26.5 51.1±25.6 0.79 
Social limitation 63.5±30.3 63.9±29.8 0.85 
Summary 49.3±22.4 49.8±21.2 0.78 
ESSI Social Support Status at Baseline 
Social support score 21.0±5.4 22.4±4.3 <0.001 
Low social support score 55 (24.0) 116 (13.3) <0.001 
Provider Characteristics 
Specialty   <0.001 
Interventional 
cardiologist 
53 (22.9) 394 (44.9)  
Cardiologist 17 (7.4) 100 (11.4)  
Vascular surgeon 150 (64.9) 315 (35.9)  
Vascular medicine 
specialist 
4 (1.7) 50 (5.7)  
Physician assistant 0 (0.0) 1 (0.1)  
Nurse practitioner 0 2 (0.2)  
Other 7 (3.0) 16 (1.8)  
Country   <0.001 
USA 78 (33.8) 590 (67.2)  
Netherlands 122 (52.8) 235 (26.8)  
Australia 31 (13.4) 53 (6.0)  
Decision-making 
Preferred role type at 
baseline 
  <0.001 
Passive 112 (54.4) 347 (41.4)  
Shared/Autonomous 94 (45.6) 492 (58.6)  
PAD treatment: Who is 
responsible for making 
treatment decisions at 3-
month time point 
  <0.001 
Doctor alone 61 (27.0) 120 (13.9)  
Mostly the doctor 59 (26.1) 179 (20.7)  
Doctor and you equally 77 (34.1) 488 (56.4)  
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 Decisional Conflict 
(N=231) 
No Decisional 
Conflict (N=878) 
P-Value 
Mostly you 21 (9.3) 46 (5.3)  
You alone 8 (3.5) 33 (3.8)  
Actual decision-making 
discordance 
46 (22.2) 127 (15.1) 0.013 
Quality of Care Indicators Prior to Treatment 
Statin 2010 performance 
measure 
189 (81.8) 726 (82.7) 0.76 
Antiplatelet 
(ASA/Clopidogrel) 2010 
performance measure 
193/202 (86.9) 770/792 (90.0) 0.19 
Smoking cessation 2010 
performance measure  
65/202 (69.1) 234/811 (77.7) 0.09 
Supervised exercise 
program performance 
measure 
90/107 (42.1) 168/217 (20.3) <0.001 
Participation in Exercise Therapy at 3 Month Interview 
Participated in Exercise 
Therapy Following 
Diagnosis 
93 (40.2) 273 (31.0) 0.007 
Type of Exercise Program    
PAD-specific, 
unsupervised 
77 (33.3) 174 (19.8) 0.001 
PAD-specific, 
supervised 
9 (3.8) 36 (4.1) 0.24 
Non-PAD specific 9 (3.8) 38 (4.3) 0.29 
Still participating 68 (29.4) 188 (21.4) 0.91 
Stopped or did not 
participate 
   
Not offered 70 (30.3) 218 (24.8) 0.004 
Medical reasons 15 (6.4) 33 (3.7) 0.035 
Prefer walking 55 (23.8) 377 (42.9) 2.0 E-6 
Insurance reasons 5 (2.1) 13 (1.4) 0.36 
Cost reasons 6 (2.5) 12 (1.3) 0.13 
Scheduling reasons 4 (1.7) 8 (0.9) 0.26 
No program available 4 (1.7) 11 (1.2) 0.50 
Felt better 6 (2.5) 13 (1.4) 0.23 
Felt worse 10 (4.3) 30 (3.4) 0.41 
Side effect reasons 3 (1.2) 2 (0.2) 0.050 
Completed program 2 (0.8) 6 (0.6) 1.00 
Other reasons 24 (10.3) 96 (10.9) 0.80 
Medication Adherence at Three Month Interview—Reason for Not Taking Medications 
Forgot to take  64 (27.7) 320 (36.4) 0.053 
Have too many  3 (1.2) 10 (1.1) 0.71 
Too confusing 0 (0.0) 6 (0.6) 0.39 
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 Decisional Conflict 
(N=231) 
No Decisional 
Conflict (N=878) 
P-Value 
Cost too much 3 (1.2) 6 (0.6) 0.37 
Copay is too high 1 (0.4) 1 (0.1) 0.31 
Could not attain  5 (2.1) 22 (2.5) 1.00 
Unwanted side-effects 7 (3.0) 18 (2.0) 0.16 
Began feeling worse 5 (2.1) 7 (0.7) 0.033 
Began feeling better 1 (0.4) 5 (0.5) 1.00 
Fear the medication 1 (0.4) 3 (0.3) 1.00 
Wanted natural 
remedies 
0 (0.0) 1 (0.1) 1.00 
Other reason 12 (5.1) 22 (2.5) 0.006 
Abbreviations: SD, standard deviation; TIA, transient ischemic attack; AMI, Acute 
Myocardial Infarction; PCI, percutaneous coronary intervention; CABG, coronary artery 
bypass graft; BMI, body mass index; EP device, electrophysiologic device; ABI, ankle 
brachial index; PAD, peripheral arterial disease; BMS, bare metal stent; DEB, drug eluting 
balloon; DES drug eluting stent 
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Table 7. Treatment Strategy and PAQ Scoring for Decisional Conflict or No Decisional 
Conflict Categories. Counts, Local Percentages, and P-Values. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Decisional Conflict 
(N=231) 
No Decisional 
Conflict (N=878) 
P-Value 
Treatment in First Three Months 
Treatment strategy   <0.001 
Invasive 27 (11.7) 196 (22.3)  
Non-invasive 204 (88.3) 682 (77.7)  
Endovascular treatment 24 (10.5) [3] 176 (20.4) [17] <0.001 
Surgical treatment 4 (1.8) [3] 25 (2.9) [17] 0.34 
PAQ summary score 
Baseline 49.3±22.4 [1] 49.8±21.2 [0] 0.78 
12 Month 67.1±27.2 [39] 71.8±24.7 [126] 0.022 
PAQ Change (12 Month 
minus baseline)  
16.21±25.0 [39] 21.61±23.9 0.006 
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Table 8. Analysis Covariates Included in Logistic Regression and Multivariate Linear 
Regression Models 
Block Covariates Included 
1 
Country, clinic site, provider specialty, and PAQ summary baseline 
scores (for multivariable linear regression only) 
2 Age, sex, and race 
3 Marital, education, and insurance statuses 
4 Ankle brachial index, proximal versus distal disease, history of PAD 
5 
History of myocardial infarction, transient ischemic attack, 
cerebrovascular accident, coronary artery bypass graft, diabetes, and 
smoking status 
6 
Cross variable between exercise therapy and treatment type (for 
multivariable linear regression only) 
7 Passive versus not passive preference 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 32
Table 9. Sequential Logistic Regression Results. Odds Ratios (OR) and 95% CI are listed for 
the association between decisional conflict and primary PAD treatment strategy by each 
block of variables entered into the model. 
Decisional Conflict OR 95% CI P-Value 
Block 1—adjusting for country, provider 
site, and provider specialty 
0.61 0.36-1.03 0.07 
Block 2—adjusting for age, sex, and race 0.61 0.36-1.04 0.07 
Block 3—adjusting for marital, education, 
and insurance statuses 
0.61 0.36-1.04 0.07 
Block 4—adjusting for ABI, distal versus 
proximal disease, and history of PAD 
0.60 0.35-1.03 0.07 
Block 5—adjusting for history of MI, TIA, 
CVA, CABG, Diabetes, and smoking 
status 
0.58 0.34-1.00 0.050 
Block 6—adjusting for passive versus not 
passive preference 
0.58 0.34-1.00 0.050 
Abbreviations: ABI, ankle brachial index; PAD, peripheral artery disease; MI, myocardial 
infarction; TIA, transient ischemic attack; CVA, cerebrovascular accident; CABG, coronary 
artery bypass graft 
Variables included in the analysis are shown in Table 8 
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Table 10. Sequential Logistic Regression Covariates. Odds Ratios (OR) and 95% CI are 
listed for the last step-wise block. 
 OR 95% CI P-Value 
Clinic Location (Site)  1.06 1.01-1.11 0.016 
Provider Specialty 0.88 0.66-1.17 0.37 
Country 0.82 0.45-1.51 0.52 
Decisional Conflict Present 0.58 0.34-1.00 0.050 
Age 0.98 0.96-1.01 0.16 
Race 1.71 0.90-3.24 0.10 
Sex 0.59 0.37-0.94 0.025 
Marital Status 0.99 0.86-1.12 0.83 
Educational Status 1.06 0.65-1.72 0.83 
Insurance Status 0.94 0.46-1.93 0.87 
ABI 0.23 0.07-0.73 0.013 
Distal versus proximal disease 1.57 0.81-3.04 0.18 
History of PAD 1.80 1.07-3.06 0.028 
History of MI 1.05 0.59-1.86 0.88 
History of TIA 0.55 0.18-1.69 0.29 
History of CVA 0.75 0.32-1.75 0.49 
History of CABG 0.90 0.48-1.69 0.74 
History of DM 1.27 0.80-2.03 0.31 
Passive role versus not passive role 0.98 0.62-1.56 0.95 
Abbreviations: TIA, transient ischemic attack; MI, Myocardial Infarction; CABG, coronary 
artery bypass graft; ABI, ankle brachial index; PAD, peripheral arterial disease 
Variables included in the analysis are shown in Table 8 
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Table 11. Sequential Multivariable Linear Regression Results. Odds Ratios (OR) and 95% CI 
are listed for the association between decisional conflict and 12 month PAQ summary scores 
by each block of variables entered into the model. 
Decisional Conflict B 95% CI P-Value 
Block 1—adjusting for country, provider 
site, provider specialty, and PAQ 
baseline scores 
-4.77 -9.51-(-0.03) 0.049 
Block 2—adjusting for age, sex, and race -5.74 -10.41-(-1.08) 0.016 
Block 3—adjusting for marital, 
education, and insurance status 
-5.70 -10.38-(-1.03) 0.017 
Block 4—adjusting for ABI, distal versus 
proximal disease, and history of PAD 
-5.68 -10.37-(-0.99) 0.018 
Block 5—adjusting for history of MI, 
TIA, CVA, CABG, Diabetes, and 
smoking status 
-5.55 -10.25-(-0.85) 0.021 
Block 6—adjusting for cross variable 
between exercise type and treatment type 
-4.68 -9.33-(-0.02) 0.049 
Block 7—adjusting for passive versus not 
passive preference 
-4.72 -9.38-(-0.06) 0.047 
Abbreviations: PAQ, peripheral artery questionnaire; ABI, ankle brachial index; PAD, 
peripheral artery disease; MI, myocardial infarction; TIA, transient ischemic attack; CVA, 
cerebrovascular accident; CABG, coronary artery bypass graft 
Variables included in the analysis are shown in Table 8 
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Figure 1. Shared Decision-making Continuum Adapted from Elwyn et al. 2014. Moving from Left 
to Right on the Continuum Through Each Numbered Action Steps Moves Towards More Informed 
Decision Preferences. 
3. Patient’s 
Values 
Defined 
4. Informed 
Decision 
Made 
2. Treatment 
Options 
Described 
1. Care 
Team 
Discussion 
Less 
Informed 
Decision 
Preference 
More 
Informed 
Decision 
Preference 
Shared Decision-making Continuum 
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Figure 2. Long-term Effects of Shared Decision-making. Adapted from Elwyn et al. 
2016. Moving Clockwise from the Top Left, the Effects (Proximal, Distal, and Distant) 
of Shared Decision Making are Outlined. 
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Figure 3. Case Report Form Data Collected as Potential Moderators and Mediators for Outcomes in New 
PAD Patients 
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12-Month Follow-up 
N=1013 
6-Month Follow-up 
N=1090 
 
3-Month Follow-up 
N=1160 
 
Enrolled 
N=1275 
 
Eligible 
N=1608 
 
Screened 
N=3637 
 
Refused N=246 
Unreachable N=87 
Refused N=78 
Died N=6 
Attrition N=24 
Too Ill N=9 
Refused N=127 
Died N=17 
Attrition N=28 
Too Ill N=13 
Refused N=125 
Died N=34 
Attrition N=28 
Too Ill N=6 
Figure 4. PORTRAIT Flowchart for Patients Screened, Eligible, Enrolled and 
Followed Including Attrition Due to Refusal, Unable to Reach, Death, General 
Attrition, and Being Too Ill 
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Figure 5. Map of the 10 PORTRAIT Enrollment Sites in the United States of 
America 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
1. St. Luke’s Mid-America Heart Institute, Kansas City, MO (David Safley, MD) 
2. Truman Medical Center, Kansas City, MO (Mark Friedell, MD) 
3. Ochsner St. Anna General Hospital, New Orleans, LA (Christopher White, MD) 
4. Duke University Medical Center, Durham, NC (Manesh Patel, MD) 
5. St. Joseph Mercy, Ann Arbor, MI (Herbert Aronow, MD) 
6. Cleveland Clinic, Cleveland, OH (Medhi Shishehbor, MD) 
7. Miriam Hospital, Providence, RI (Peter Soukas, MD) 
8. Rhode Island HS, Providence, RI (Dawn Abbott, MD) 
9. Yale New Haven Hospital, New Haven, CT (Carlos Mena, MD) 
10. Bridgeport Hospital, Bridgeport, CT (Ed Tuohy, MD) 
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Figure 7. Map of the 5 PORTRAIT Enrollment Sites in The Netherlands 
Figure 6. Map of the 1 PORTRAIT Enrollment Site in Australia 
1. St. Elisabeth Hospital, Tillburg (Patrick 
Vriens, MD, PhD) 
2. Twee Steden Hospital, Tillburg (Marnix De 
Fijter, MD, PhD) 
3. Zorgsaam Terneuzen (Alex Derom, MD) 
4. Albert Schweitzer Hospital, Dordrecht 
(Rudolf Tutein-Nolthenius, MD, PhD) 
5. St. Antonius Hospital, Nieuwegein (Jean-
Paul de Vries, MD, PhD) 
1
2
3 
4 
5 
1. Queen Elisabeth Hospital, Adelaide (John 
Beltrame, MD, PhD; Rob Fitridge, MBBS MS 
FRACS) 
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Figure 8. Ordered Median Odds Ratios for Site Variability as a Bar Graph. Probability of 
Decisional Conflict on the Y-Axis, Site on the X-Axis. Counts Associated with Site on the 
X-Axis are Number of Participants Included in Decisional Conflict Analysis per Site, Total 
N=1,109. 
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